RE:RE:you just can't make this stuff up....
I thought the same thing when I first heard the strategy / concept .... but I do think management finally have their ducks in a row on this one. The shorts will play on the fact that these guys have made deal claims for a long time now...and they HAVE.... but they have never had the compelling human efficacy data from multiple trials that they have in hand now.
Yes they are smallish samples, and the value will reflect that .... but they have been de risked to the point where deals can get done at good value. The time has come for management to get deals done for credibility of the drugs, the platform.... and to set the valuation bar for subsequent deals for other indications or geographies. THEY KNOW THIS and are ON IT
I could see deals in the $25-$50mm range. And while those arent blockbusters, they will achieve ALOT... alleviate cash concerns, validate the platform... and give analysts the ability to reduce the current discount rate they apply. All while making it very clear just how valuable these drugs can be, particularly these kind of deals can help facilitate getting these drugs closer to the finish line in the largest indications in the largest markets....